On May 27, GenScript Biotech rose 5.12% in regular trading, trading at HKD 14.04/share, with trading volume of HKD 45.87 million.

On the news front, GenScript previously announced that its associate company Legend Biotech will present multiple research results at the ASCO Annual Meeting. A rapid oral presentation will highlight Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy for relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma. New CARVYKTI data will also be disclosed at the conference.

The expansion of CAR-T therapy into solid tumor indications opens significant growth potential for the company. Meanwhile, market discussions around GenScript's valuation inversion — where its total market capitalization (approximately USD 4.78 billion) remains below the value of its approximately 47% stake in Legend Biotech (approximately USD 2.64 billion), implying negative value for its remaining life sciences, CDMO, and synthetic biology businesses — have further supported short-term sentiment recovery and driven the share price rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)